Skip to main content
Contact Us
Subscribe
E-Edition
61°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
502.92
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
58
59
Next >
Vertex Pharmaceuticals Shares Are Up Today: What's Going On?
January 31, 2025
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen its position in both pain management and gene therapy.
Via
Benzinga
Charter Communications Posts Upbeat Earnings, Joins Atlassian, SkyWest, Eastman Chemical, AbbVie And Other Big Stocks Moving Higher On Friday
January 31, 2025
Via
Benzinga
Friday's pre-market session: top gainers and losers in the S&P500 index
January 31, 2025
Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session.
Via
Chartmill
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
January 31, 2025
From
Vertex Pharmaceuticals
Via
Business Wire
Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (21 Ratings)
January 30, 2025
Via
Benzinga
Is Vertex Pharmaceuticals Stock a Buy in 2025?
January 26, 2025
Via
The Motley Fool
Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller
January 30, 2025
The first-in-class drug had suffered a setback in December.
Via
Investor's Business Daily
Exposures
Product Safety
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
January 30, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
This Everest Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
January 30, 2025
Via
Benzinga
Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
January 27, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
How Is The Market Feeling About Vertex Pharmaceuticals?
January 15, 2025
Via
Benzinga
Forecasting The Future: 23 Analyst Projections For Vertex Pharmaceuticals
January 10, 2025
Via
Benzinga
Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever.
January 25, 2025
Via
The Motley Fool
2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher
January 24, 2025
Via
The Motley Fool
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
January 23, 2025
MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.
Via
MarketBeat
Exposures
Product Safety
Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever
January 21, 2025
Via
The Motley Fool
8 Health Care Stocks Whale Activity In Today's Session
January 20, 2025
Via
Benzinga
3 Unstoppable Stocks to Buy in 2025
January 18, 2025
Via
The Motley Fool
HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws'
January 16, 2025
HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its gene-editing therapy for sickle cell disease.
Via
Benzinga
Vertex's Pain Drug: Big Pharma's Next Major Success?
January 16, 2025
Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market.
Via
MarketBeat
Exposures
Product Safety
Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?
January 16, 2025
Via
The Motley Fool
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
January 14, 2025
Via
Benzinga
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
January 14, 2025
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and strengthens its global drug pipeline.
Via
Benzinga
Exposures
Product Safety
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
January 14, 2025
Via
The Motley Fool
My 3 Highest-Conviction Growth Stocks to Buy in 2025
January 13, 2025
Via
The Motley Fool
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
January 12, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure
January 10, 2025
Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI start-up.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
January 10, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
January 10, 2025
From
Zai Lab Limited
Via
Business Wire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
January 09, 2025
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Government
Exposures
Artificial Intelligence
Political
< Previous
1
2
3
4
5
6
7
8
9
...
58
59
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.